The Cyprus Institute of Neurology and Genetics (CING) has launched two new research programmes to improve the classification of genetic variants linked to breast and ovarian cancer, a key step toward more accurate counselling and personalised treatment.
The projects – BcRAVE and OVATION – will run for two years with a combined funding of €329,000 under the EU-backed Cohesion Policy Programme Thaleia 2021–2027, coordinated through the Research and Innovation Foundation
